Figure S5 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

• Combination treatment significantly enhances efficacy against pancreatic cancer cells lacking MTAP.
• Analysis showed synergistic effects between PRMT5 inhibitors and KRAS inhibitors in vitro.
• This approach opens new avenues for targeted therapies in specific pancreatic cancer genotypes.
• Further studies are necessary for clinical validation and effectiveness assessments in human trials.

Abstract